Devyser Diagnostics AB (publ) (STO:DVYSR)

Market Cap	1.09B -49.8%
Revenue (ttm)	253.60M +4.4%
Net Income	25.50M
EPS	1.50
Shares Out	16.89M
PE Ratio	42.79
Forward PE	40.18
Dividend	n/a
Ex-Dividend Date	n/a

Volume	22,367
Open	65.20
Previous Close	64.80
Day's Range	63.00 - 65.90
52-Week Range	48.50 - 129.00
Beta	0.80
Analysts	Buy
Price Target	96.25 (+49.69%)
Earnings Date	Nov 3, 2026

About Devyser Diagnostics AB

Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, hereditary cancer, and transfusion medicine products; and Amplicon Suite and Advyser for cloud-based software solutions for data analysis and the inter...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2004
• Employees: 110
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: DVYSR

Financial Performance

In 2025, Devyser Diagnostics AB's revenue was 250.50 million, an increase of 15.49% compared to the previous year's 216.90 million. Losses were -8.40 million, -86.34% less than in 2024.

Analyst Summary

According to 2 analysts, the average rating for DVYSR stock is "Buy." The 12-month stock price target is kr 96.25, which is an increase of 49.69% from the latest price.

Price Target

kr 96.25

(49.69% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and QUODD

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by QUODD.

Last checked:

Nov 4, 2026

Data Sources Report a data error